Effects of the Anti-Epidermal Growth Factor Receptor Antibody Cetuximab on Cholangiocarcinoma of the Liver

Publisher： Karger

E-ISSN： 2296-5262|30|3|129-131

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.30, Iss.3, 2007-02, pp. : 129-131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody

By  

Oncology, Vol. 92, Iss. 4, 2017-02 ,pp. : 205-212

Karger

Access to resources Recommend Favorite

Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 Upregulates p27KIP1 and p15INK4B and Induces G1 Arrest in Oral Squamous Carcinoma Cell Lines

By  

Oncology, Vol. 63, Iss. 1, 2002-08 ,pp. : 92-98

Karger

Access to resources Recommend Favorite

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

By  

Oncology, Vol. 72, Iss. 3-4, 2007-12 ,pp. : 152-159

Karger

Access to resources Recommend Favorite

Risk of High-Grade Skin Rash in Cancer Patients Treated with Cetuximab – an Antibody against Epidermal Growth Factor Receptor: Systemic Review and Meta-Analysis

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 124-133

Karger

Access to resources Recommend Favorite

Reply to colorectal carcinomas, KRAS p.G13D mutant allele–specific imbalance, and anti–epidermal growth factor receptor therapy

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4366-4367

John Wiley & Sons Inc

Access to resources Recommend Favorite